Patents by Inventor Roland Pfau

Roland Pfau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • Publication number: 20200123140
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200121691
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200123141
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20190175605
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Georg DAHMANN, Cornelia DORNER-CIOSSEK, Lothar KUSSMAUL, Roland PFAU, Dieter WIEDENMAYER
  • Patent number: 9676781
    Abstract: The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R3, R4 and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: June 13, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Georg Dahmann, Kai Gerlach, Roland Pfau, Wolfgang Wienen, Annette Schuler-Metz, Sandra Handschuh, Herbert Nar
  • Publication number: 20150252050
    Abstract: The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R3, R4 and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 10, 2015
    Inventors: Henning PRIEPKE, Georg DAHMANN, Kai GERLACH, Roland PFAU, Wolfgang WIENEN, Annette SCHULER-METZ, Sandra HANDSCHUH, Herbert NAR
  • Patent number: 9062034
    Abstract: The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R3, R4 and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 23, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Georg Dahmann, Kai Gerlach, Roland Pfau, Wolfgang Wienen, Annette Schuler-Metz, Sandra Handschuh, Herbert Nar
  • Patent number: 9040565
    Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: May 26, 2015
    Assignee: Orexo AB
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer, Juergen Mack, Dirk Stenkamp
  • Patent number: 8951999
    Abstract: This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R1, R2, R7, Ra, Rb, Q3, Q4, Q6, Z2, Z4, Z5, Z6 and W have meanings given in the description.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Orexo AB
    Inventors: Henning Priepke, Henri Doods, Raimund Kuelzer, Roland Pfau, Dirk Stenkamp, Robert Roenn, Benjamin Pelcman
  • Patent number: 8921405
    Abstract: The present invention relates to compounds of general formula I in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: December 30, 2014
    Assignee: Orexo AB
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Klaus Klinder, Raimund Kuelzer, Dimitrijs Lubriks, Juergen Mack, Benjamin Pelcman, Henning Priepke, Robert Roenn, Dirk Stenkamp, Edgars Suna
  • Patent number: 8916599
    Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 23, 2014
    Assignee: Orexo AB
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer, Juergen Mack, Henning Priepke, Dirk Stenkamp
  • Patent number: 8791103
    Abstract: The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: July 29, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Kai Gerlach, Roland Pfau, Norbert Hauel, Iris Kauffmann-Hefner, Georg Dahmann, Herbert Nar, Sandra Handschuh, Wolfgang Wienen, Annette Schuler-Metz
  • Patent number: 8759537
    Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7, R8 have meanings given in the description.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: June 24, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Henri Doods, Raimund Kuelzer, Roland Pfau, Dirk Stenkamp, Benjamin Pelcman, Robert Roenn
  • Patent number: 8703796
    Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: April 22, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer
  • Patent number: 8674113
    Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: March 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Henri Doods, Alexander Heim-Riether, Raimund Kuelzer, Roland Pfau, Klaus Rudolf, Dirk Stenkamp
  • Patent number: 8598190
    Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 3, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer